RWD172 Healthcare Utilization and Costs Among Patients With Episodic Migraine Initiating Galcanezumab Versus Rimegepant for Migraine Prevention in the United States
Abstract
Authors
G Kim M Hoyt J Durica A Zakharyan A Wallem L Viktrup